This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Debio 1144

Debiopharm S.A.

Drug Names(s): ASP-08126

Description: Debio 1144 (ASP-08126) is an orally available small molecule that inhibits several tyrosine kinases implicated in many aspects of cancer development including tumor growth, metastasis and tumor angiogenesis. It is expected to be effective in the treatment of various solid tumours as a mono-therapeutic agent or in combination with other anti-cancer therapies.

Deal Structure: Debiopharm and Ascepion
In June 2012, Debiopharm and Ascepion entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm).

Partners: Ascepion Pharmaceuticals, Inc.


Debio 1144 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug